Jack on antibody-drug conjugates: a quiet, targeted strike

A quiet strike, carefully addressed By Jack

This morning’s subject is a small delivery system with a powerful cargo: an antibody-drug conjugate, or ADC.

Think of a precise, quiet strike. The antibody recognizes its target; the attached drug supplies the potent payload. More specifically, an ADC joins a monoclonal antibody to a cytotoxic drug—a drug toxic to cells. The antibody’s selectivity is meant to direct that payload to diseased cells while limiting damage to healthy tissue. The address matters as much as the cargo.

That is the aim, not a guarantee that healthy tissue goes untouched. “Targeted” describes the approach; it is not a synonym for harmless.

The idea has a long runway. In the early 1900s, Paul Ehrlich proposed a “magic bullet” that could selectively target diseased cells. ADCs connect that century-old ambition to modern cancer therapy: a targeting antibody paired with a potent drug.

In a Drug Discovery World overview dated 28 October 2025, Janet Sasso, an information scientist at CAS, reports that 15 ADCs have received regulatory approval. That figure is the source’s count, not a newly checked total.

A century-old metaphor, then, with a concrete molecular design: recognize the target, carry the payload, aim to spare healthy tissue.